The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Abstract
Microtubule-stabilizing agents (MTSAs), including the taxanes and epothilones, are effective chemotherapeutic agents for the treatment of many cancers. Neuropathy is a major adverse effect of MTSA-based chemotherapy, with severe peripheral neuropathy (grade 3 or 4) occurring in as many as 30% of patients treated with a MTSA. MTSA-induced neuropathy usually resolves gradually after cessation of the treatment. The most reliable method to accurately assess MTSA-induced neuropathy is by clinical evaluation, although additional techniques are being developed and evaluated. Among MTSA-induced neuropathy, the most extensively studied is that induced by taxanes; such a neuropathy usually presents as sensory neuropathy and is more common with paclitaxel than docetaxel. The incidence of MTSA-induced neuropathy seems to depend on the MTSA dose per treatment cycle, the schedule of treatment, and the duration of the infusion. Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy. In the future, research should focus on elucidating the mechanism of MTSA-induced neuropathy, developing reliable in vivo and in vitro preclinical models to study MTSA-induced neuropathy, developing a more reliable grading system for MTSA-induced neuropathy, developing more reliable methods for evaluating MTSA-induced neuropathy, and evaluating the efficacy of potential neuroprotective agents in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
An objective and standardized test of hand function.
Jebsen, R. H., Taylor, N. F., Trieschmann, R. B., Trotter, M. J., & Howard, L. (1969) · PubMed · Cited by 1,705
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 641
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic
Perkins, B. A., Olaleye, D., Zinman, B., & Bril, V. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.250 · Cited by 585
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.012 · Cited by 583
Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells
Yvon, A.-M. C., Wadsworth, P., & Jordan, M. A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.947 · Cited by 553
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Ruff, R. M., & Parker, S. B. (1993) · Perceptual and Motor Skills · doi:10.2466/pms.1993.76.3c.1219 · Cited by 488
Phase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 378
Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G. M., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Van Vreckem, A., Sylvester, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.724 · Cited by 364
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363
Epothilones: Mechanism of Action and Biologic Activity
Goodin, S., Kane, M. P., & Rubin, E. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.001 · Cited by 346
Hensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3333 · Cited by 335
Taxol produces a predominantly sensory neuropathy
Lipton, R. B., Apfel, S. C., Dutcher, J. P., Rosenberg, R., Kaplan, J., Berger, A., Einzig, A. I., Wiernik, P., & Schaumburg, H. H. (1989) · Neurology · doi:10.1212/wnl.39.3.368 · Cited by 318
Ravdin, P. M., Burris, H. A., Cook, G., Eisenberg, P., Kane, M., Bierman, W. A., Mortimer, J., Genevois, E., & Bellet, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 317
Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9102 · Cited by 290
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11578 · Cited by 286
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Schuchter, L. M., Hensley, M. L., Meropol, N. J., & Winer, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.178 · Cited by 262
The Effect of Improved Glycemic Control on Cognitive Functions in the Elderly Patient With Diabetes
Meneilly, G. S., Cheung, E., Tessier, D., Yakura, C., & Tuokko, H. (1993) · Journal of Gerontology · doi:10.1093/geronj/48.4.m117 · Cited by 222
Low, J. A., Wedam, S. B., Lee, J. J., Berman, A. W., Brufsky, A., Yang, S. X., Poruchynsky, M. S., Steinberg, S. M., Mannan, N., Fojo, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.024 · Cited by 215
Self-citationCisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients
Weijl, N. I., Hopman, G. D., Wipkink-Bakker, A., Lentjes, E. G. W. M., Berger, H. M., Cleton, F. J., & Osanto, S. (1998) · Annals of Oncology · doi:10.1023/a:1008407014084 · Cited by 214
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial
Argyriou, A. A., Chroni, E., Koutras, A., Ellul, J., Papapetropoulos, S., Katsoulas, G., Iconomou, G., & Kalofonos, H. P. (2005) · Neurology · doi:10.1212/01.wnl.0000148609.35718.7d · Cited by 209
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998) · Annals of Oncology · doi:10.1023/a:1008344507482 · Cited by 207
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing
Forsyth, P. A., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P., & Deangelis, L. M. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005805907311 · Cited by 199
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., Martone, L., Curley, T., DeLaCruz, A., Scher, H. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.042 · Cited by 189
Grading of chemotherapy-induced peripheral neuropathy
Postma, T. J., & Heimans, J. J. (2000) · Annals of Oncology · doi:10.1023/a:1008345613594 · Cited by 170
Taxol Neuropathy: Electrodiagnostic and Sural Nerve Biopsy Findings
Sahenk, Z. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540190110024 · Cited by 163
Kamei, N., Yamane, K., Nakanishi, S., Yamashita, Y., Tamura, T., Ohshita, K., Watanabe, H., Fujikawa, R., Okubo, M., & Kohno, N. (2004) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2003.12.006 · Cited by 162
Hussain, M., Tangen, C. M., Lara, P. N., Vaishampayan, U. N., Petrylak, D. P., Colevas, A. D., Sakr, W. A., & Crawford, E. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4448 · Cited by 159
Bianchi, G., Vitali, G., Caraceni, A. T., Ravaglia, S., Capri, G., Cundari, S., Zanna, C., & Gianni, L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.028 · Cited by 152
Smith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 151
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat, L. T., Papadopoulos, K. P., Lange, D., Leuin, S. C., Kaufman, E. A., Donovan, D., Frederick, D., Bagiella, E., Tiersten, A., NICHOLS, G. L., et al. (2001) · PubMed · Cited by 149
Increased HER2 With U.S. Food and Drug Administration-Approved Antibody
Roche, P. C., & Ingle, J. N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.434 · Cited by 147
Wlds mice are resistant to paclitaxel (taxol) neuropathy
Wang, M. S., Davis, A. A., Culver, D. G., & Glass, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10300 · Cited by 146
Motor neuropathy due to docetaxel and paclitaxel
Freilich, R. J., Balmaceda, C. M., Seidman, A. D., Rubin, M., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.47.1.115 · Cited by 144
Mielke, S., Sparreboom, A., Steinberg, S. M., Gelderblom, H. A. J., Unger, C., Behringer, D. M., & Mross, K. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0298 · Cited by 144
Monk, B. J., Huang, H. Q., Cella, D. F., & Long, H. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.522 · Cited by 131
Fosså, S. D., de Wit, R., Roberts, J. T., Wilkinson, P. M., Mulder, P. H. M. D., Mead, G. M., Cook, P., de Prijck, L., Stenning, S. P., Aaronson, N. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.075 · Cited by 130
Cavaletti, G., Cavalletti, E., Montaguti, P., Oggioni, N., Negri, O. D., & Tredici, G. (1997) · PubMed · Cited by 124
Peripheral neurotoxicity induced by docetaxel
Hilkens, P. H. E., Verweij, J., Stoter, G., Vecht, C. J., van Putten, W. L. J., & van den Bent, M. J. (1996) · Neurology · doi:10.1212/wnl.46.1.104 · Cited by 119
Approach to Peripheral Neuropathy and Neuronopathy
Barohn, R. J. (1998) · Seminars in Neurology · doi:10.1055/s-2008-1040857 · Cited by 118
Maser, R. E., Nielsen, V. K., Bass, E. B., Manjoo, Q., Dorman, J. S., Kelsey, S. F., Becker, D. J., & Orchard, T. J. (1989) · Diabetes Care · doi:10.2337/diacare.12.4.270 · Cited by 118
Assessing the Reliability of Two Toxicity Scales: Implications for Interpreting Toxicity Data
Brundage, M., Pater, J. L., & Zee, B. C.-Y. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1138 · Cited by 115
Maestri, A., Ceratti, A. D. P., Cundari, S., Zanna, C., Cortesi, E., & Crinò, L. (2005) · Tumori Journal · doi:10.1177/030089160509100206 · Cited by 113
Wenzel, L. B., Huang, H. Q., Monk, B. J., Rose, P. G., & Cella, D. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.147 · Cited by 110
Theiß, C., & Meller, K. (2000) · Cell and Tissue Research · doi:10.1007/s004410050019 · Cited by 110
Theiß, C., & Meller, K. (1999) · Cell and Tissue Research · doi:10.1007/s004419900120 · Cited by 108
Peripheral neuropathy secondary to docetaxel (Taxotere)
New, P., Jackson, C. E., Rinaldi, D. A., Burris, H. A., & Barohn, R. J. (1996) · Neurology · doi:10.1212/wnl.46.1.108 · Cited by 98
Davis, I. D., Kiers, L., MacGregor, L., Quinn, M. A., Arezzo, J. C., Green, M., Rosenthal, M. A., Chia, M. M., Michael, M., Bartley, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1655 · Cited by 96
Taxol-induced neuropathy: short-term effects of local injection
R�ytt�, M., Horwitz, S. B., & Raine, C. S. (1984) · Journal of Neurocytology · doi:10.1007/bf01148489 · Cited by 91
Cull, A., Howat, S., Greimel, E., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00369-5 · Cited by 90
Wang, M. S., Fang, G., Culver, D. G., Davis, A. A., Rich, M. M., & Glass, J. D. (2001) · Annals of Neurology · doi:10.1002/ana.10039 · Cited by 90
CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia
Aplenc, R., Glatfelter, W., Han, P. P., Rappaport, E. F., La, M., Cnaan, A., Blackwood, M. A., Lange, B. J., & Rebbeck, T. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04430.x · Cited by 82
Moore, D. H., Donnelly, J. P., McGuire, W. P., Almadrones, L., Cella, D. F., Herzog, T. J., & Waggoner, S. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.086 · Cited by 80
Amelioration of Experimental Cisplatin and Paclitaxel Neuropathy with Glutamate
Boyle, F. M., Wheeler, H., & Shenfield, G. M. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006124917643 · Cited by 79
Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel
Openshaw, H., Beamon, K., Synold, T. W., Longmate, J., Slatkin, N. E., Doroshow, J. H., Forman, S. J., Margolin, K. A., Morgan, R. J., Shibata, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0772-03 · Cited by 78
Hilpert, F., Stähle, A., Tomé, O., et al. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0782-y · Cited by 70
The Gene for Slow Wallerian Degeneration (Wlds) Is Also Protective against Vincristine Neuropathy
Wang, M.-S., Wu, Y., Culver, D. G., & Glass, J. D. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0334 · Cited by 69
The taxoids: same roots, different drugs.
Hoff, D. D. V. (1997) · PubMed · Cited by 66
Akerley, W., Herndon, J. E., Egorin, M. J., Lyss, A. P., Kindler, H. L., Savarese, D. M. F., Sherman, C. A., Rosen, D. M., Hollis, D. R., Ratain, M. J., et al. (2003) · Cancer · doi:10.1002/cncr.11375 · Cited by 61
Morphological evidence of the inhibitory effect of taxol on the fast axonal transport
Nakata, T., & Yorifuji, H. (1999) · Neuroscience Research · doi:10.1016/s0168-0102(99)00074-7 · Cited by 61
Amifostine: chemotherapeutic and radiotherapeutic protective effects
Santini, V. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.3.479 · Cited by 61
Medication-induced peripheral neuropathy
Weimer, L. H. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0043-8 · Cited by 58
The Impact of Diabetes Mellitus on the Toxicity of Therapy for Advanced Ovarian Cancer
Gogas, H. J., Shapiro, F., Aghajanian, C. A., Fennelly, D. W., Almadrones, L., Hoskins, W. J., & Spriggs, D. R. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0090 · Cited by 53
Hand Function in Patients With Diabetes Mellitus
Casanova, J. E., CASANOVA, J. S., & Young, M. (1991) · Southern Medical Journal · doi:10.1097/00007611-199109000-00013 · Cited by 50
Glutamine does not prevent paclitaxel-associated myalgias and arthralgias.
Jacobson, S. D., Loprinzi, C. L., Sloan, J. A., Wilke, J. L., Novotny, P. J., Okuno, S. H., Jatoi, A., & Moynihan, T. J. (2003) · PubMed · Cited by 42
Olney, R. K. (1998) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199803000-00005 · Cited by 34
Hausheer, F. H., Kochat, H., Parker, A. R., Ding, D., Yao, S., Hamilton, S. E., Petluru, P., Leverett, B. D., Bain, S., & Saxe, J. D. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0653-5 · Cited by 33
Neurotoxicity of cisplatin and taxol
Warner, E. (1995) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1995.05030161.x · Cited by 32
Pendyala, L., Schwartz, G. N., Smith, P. F., Zdanowicz, J., Murphy, M., & Hausheer, F. H. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0587-y · Cited by 17
Multiperspective Assessment of Peripheral Nerve Involvement in Diabetic Patients
Padua, L., Aprile, I. G., Saponara, C., Padua, L., Ghirlanda, G., Pauri, F., D’Amico, P., & Tonali, P. (2001) · European Neurology · doi:10.1159/000052132 · Cited by 12
Cited by
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Metadata
- Authors
- Lee, J. J., & Swain, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-04-01
- Volume
- 24
- Issue
- 10
- Pages
- 1633-1642
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114826333
- Cited by
- 472
- References
- 89
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.